ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ceftobiprole medocaril

Also written as “Ceftobiprole medocaril”, “Ceftobiprole medocaril sodium” and “Ceftobiprole Medocaril”.

Its studies are mostly in Community-Acquired Pneumonia · Staphylococcal Skin Infections · Endocarditis, Bacterial · Staphylococcal Infections · Neonatal Sepsis, led by 2 companies.

Drug pageCeftobiprole medocaril: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 13, 200511 company-led studies, 1 open or runningNext primary completion: Oct 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Basilea Pharmaceutica100 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
ISTxits history only11 open or runningphase 3since Oct 19, 2026Oct 19, 2026Oct 31, 2028phase 3 · NCT07929493

Also a collaborator on its studies: Innoviva Specialty Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Basilea Pharmaceutica only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First studies: 2 phase 3 studies in Skin Diseases, InfectiousFirst studyNCT00210899, NCT00228982
  2. May 12, 2006Phase 3 study in PneumoniaNCT00326287 · 638 enrolled
  3. Jul 19, 2007Phase 2 study in BacteremiaNCT00505258
  4. Sep 11, 2007Phase 3 study in FeverNCT00529282 · 2 enrolled
  5. Aug 5, 2015Phase 1 study in Bacterial InfectionsNCT02527681 · 15 enrolled · United States, Belgium, Germany and more
  6. Apr 27, 20172 phase 3 studiesNCT03138733, NCT03137173
  7. Jan 30, 2018Phase 3 study in Community-Acquired PneumoniaNCT03439124 · 138 enrolled · Bulgaria, Georgia, Hungary and more
  8. Apr 17, 2023Phase 3 study in Neonatal SepsisNCT05856227 · 9 enrolled · United States, Bulgaria, Estonia and more

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Penicillin-binding protein 1 inhibitor; Penicillin-binding protein 2 inhibitor; Penicillin-binding protein inhibitor; Penicillin-binding protein 4 inhibitor”ChEMBL 37, by rule

Studies

All 10 Basilea Pharmaceutica leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05856227Neonatal Sepsis · United States, Bulgaria, Estonia and more3CompletedDec 18, 20249
NCT03439124Community-Acquired Pneumonia · Bulgaria, Georgia, Hungary and more3CompletedMar 16, 2020138
NCT03138733Staphylococcal Infections · United States, Argentina, Bulgaria and more3CompletedMar 11, 2022390
NCT03137173Acute Bacterial Skin and Skin Structure Infections · United States, Bulgaria, Hungary and more3CompletedApr 22, 2019679
NCT02527681Bacterial Infections · United States, Belgium, Germany and more1TerminatedFeb 25, 202015
NCT00529282Fever3TerminatedJan 20082
NCT00505258Bacteremia2Withdrawn0
NCT00326287Pneumonia3CompletedJul 2007638
NCT00228982Skin Diseases, Infectious3CompletedDec 2005784
NCT00210899Skin Diseases, Infectious3CompletedOct 2006828

How it is read

Names in the registry

  • “Ceftobiprole medocaril”, 5 entries
  • “ceftobiprole medocaril”, 4 entries
  • “Ceftobiprole medocaril sodium”, 1 entry
  • “Ceftobiprole Medocaril”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.